CMPX
Compass Therapeutics, Inc.
$2.02
-0.98%
$363.8M
No data for this timeframe.
Vol
Market Cap$363.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders6 funds
Inst. Value$63.4M
Inst. Activity3 buys / 2 sells
Reddit Sentiment52° Neutral
SEC Reports4
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001738021·Prev Close $2.04
Recent Activity
May 28, 2026
other
Compass Therapeutics to Participate in Upcoming June Investor Events
<p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX)
May 21, 2026
Press
Compass Therapeutics announced a poster presentation at ASCO 2026 showing Phase 1 dose-escalation data for CTX-8371, a P
Impact 7/10
May 5, 2026
SEC
Compass Therapeutics reported Q1 2026 net loss of $18.3M ($0.10/share), slightly better than the $0.10 consensus estimat
8-K — Impact 7/10
Apr 29, 2026
SEC
Compass Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) on April 29, 2026. The filing co
DEFA14A — Impact 4/10
Apr 29, 2026
Insider
Lerner Neil sold 15,000 shares
Chief Accounting Officer @ $1.89 ($28.4K)
Apr 29, 2026
Insider
Anderman Jonathan sold 25,000 shares
General Counsel @ $1.89 ($47.3K)
Apr 27, 2026
SEC
Compass Therapeutics announced positive Phase 2/3 trial data for tovecimig in biliary tract cancer, showing statisticall
8-K — Impact 7/10
Feb 8, 2026
Insider
Schuetz Thomas J. sold 36,687 shares
CHIEF EXECUTIVE OFFICER @ $6.52 ($239.2K)
Price Targets
$8.82
+328.1% upside
Strong Buy
Current $2.06
Low $4.00
Median $7.00
High $24.00
11 analysts
$4.00
$24.00
Analyst Ratings
8Strong Buy
10Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 28, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform → Market Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 24, 2026 | Guggenheim | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 ▼ -9.1% | $-0.15 — $-0.09 | 22% YoY | 11 |
| Next Q | $-0.11 ▲ +8.6% | $-0.12 — $-0.08 | -33% YoY | 11 |
| Current FY | $-0.44 ▼ -2.1% | $-0.59 — $-0.33 | -4% YoY | 11 |
| Next FY | $-0.46 ▼ -13.0% | $-0.82 — $-0.13 | -5% YoY | 11 |
Latest Reports
BULLISH
Press
7/10
Compass Therapeutics announced a poster presentation at ASCO 2026 showing Phase 1 dose-escalation data for CTX-8371, a P
May 21, 2026
BULLISH
8-K
7/10
Compass Therapeutics reported Q1 2026 net loss of $18.3M ($0.10/share), slightly better than the $0.10 consensus estimat
May 5, 2026
NEUTRAL
DEFA14A
4/10
Compass Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) on April 29, 2026. The filing co
Apr 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $43.2M | ADD |
| FMR LLC | $13.9M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $2.2M | NEW |
| MORGAN STANLEY | $2.0M | ADD |
| BANK OF AMERICA CORP | $1.4M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 29, 2026 | Lerner Neil | A | $28.4K |
| Apr 29, 2026 | Anderman Jonathan | A | $47.3K |
| Feb 8, 2026 | Schuetz Thomas | F | $239.2K |
Reddit Sentiment
52°▲
Neutral
Bearish
Neutral
Bullish
6 institutional holders with $63.4M total value (11,814,719 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, CHARLES. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 8,048,374 | $43.2M | 68.1% | ADD +45.6% |
| 2 | FMR LLC | 2,579,711 | $13.9M | 21.8% | TRIM -37.7% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 410,157 | $2.2M | 3.5% | NEW |
| 4 | MORGAN STANLEY | 365,245 | $2.0M | 3.1% | ADD +95.4% |
| 5 | BANK OF AMERICA CORP /DE/ | 266,434 | $1.4M | 2.3% | DOUBLED +261.0% |
| 6 | WELLS FARGO & COMPANY/MN | 144,798 | $777.6K | 1.2% | DOUBLED +112.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | TRIM | 4,137,562 | 2,579,711 | -37.7% | $13.9M | 2025-Q4 |
| MORGAN STANLEY | ADD | 186,952 | 365,245 | +95.4% | $2.0M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 73,801 | 266,434 | +261.0% | $1.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 68,173 | 144,798 | +112.4% | $777.6K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 79,000 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 4,850,005 | 7,062,799 | +45.6% | $24.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 224,600 | 79,000 | -64.8% | $276.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 32,549 | 73,801 | +126.7% | $258.3K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 52,724 | 68,173 | +29.3% | $238.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 16,097 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | ADD | 152,851 | 263,526 | +72.4% | $685.2K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 839,176 | 248,749 | -70.4% | $646.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 321,500 | 224,600 | -30.1% | $584.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 383,503 | 32,549 | -91.5% | $84.6K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 51,239 | 16,097 | -68.6% | $41.9K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 378,552 | 839,176 | +121.7% | $1.6M | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 210,100 | — | $399.2K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 145,238 | 51,239 | -64.7% | $97.4K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 222,600 | 278,600 | +25.2% | $404.0K | 2024-Q4 |
| UBS Group AG | DOUBLED | 65,400 | 163,656 | +150.2% | $237.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 46,822 | 59,860 | +27.8% | $86.8K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 64,226 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 167,916 | 377,887 | +125.0% | $695.3K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 286,191 | — | $526.6K | 2024-Q3 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Lerner Neil | Chief Accounting Officer | A | 15,000 | $1.89 | $28.4K |
| Apr 29, 2026 | Anderman Jonathan | General Counsel | A | 25,000 | $1.89 | $47.3K |
| Feb 8, 2026 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | F | 36,687 | $6.52 | $239.2K |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 6.3/10.
BULLISH
8-K
7/10
Compass Therapeutics reported Q1 2026 net loss of $18.3M ($0.10/share), slightly better than the $0.
May 5, 2026
NEUTRAL
DEFA14A
4/10
Compass Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) on April 29,
Apr 29, 2026
BULLISH
8-K
7/10
Compass Therapeutics announced positive Phase 2/3 trial data for tovecimig in biliary tract cancer,
Apr 27, 2026
MIXED
8-K, PRESS-RELEASE
7/10
Compass Therapeutics reported its 2025 financial results and provided a corporate update, highlighti
Mar 5, 2026
BULLISH
7/10
Compass Therapeutics announced a poster presentation at ASCO 2026 showing Phase 1 dose-escalation da
May 21, 2026
BULLISH
8/10
Compass Therapeutics announced that tovecimig, in combination with paclitaxel, achieved a highly sta
Apr 27, 2026
NEUTRAL
5/10
Compass Therapeutics (CMPX) will host a webcast on April 27, 2026, to present topline secondary endp
Apr 24, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 20 analysts: 8 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.82 mean target
+328.1% upside
Strong Buy (1.29)
$4.00 Low
$24.00 High
| Metric | Value |
|---|---|
| Current Price | $2.06 |
| Target Low | $4.00 |
| Target Mean | $8.82 |
| Target Median | $7.00 |
| Target High | $24.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.15 | $-0.09 | 22.1% | -9.1% | 0↑ 3↓ | $-0.0B | 0.0% | 11 |
| Next Q 2026-09-30 |
$-0.11 | $-0.12 | $-0.08 | -33.0% | +8.6% | 0↑ 2↓ | $0.0B | 0.0% | 11 |
| Current FY 2026-12-31 |
$-0.44 | $-0.59 | $-0.33 | -3.9% | -2.1% | 1↑ 2↓ | $-0.0B | 0.0% | 11 |
| Next FY 2027-12-31 |
$-0.46 | $-0.82 | $-0.13 | -5.4% | -13.0% | 0↑ 6↓ | $0.0B | 1258.9% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.109 | |
| 7d ago | $-0.109 | |
| 30d ago | $-0.100 | -0.009 |
| 60d ago | $-0.096 | -0.013 |
| 90d ago | $-0.088 | -0.021 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 28, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Jan 6, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | William Blair | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 10 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 9 | 12 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
52°
Neutral
Bearish
Neutral
Bullish
23 mentions
7 bullish
6 bearish
21 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 25, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 25, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 29, 2026 | 2 | 33° Cool | 0 | 2 | 2 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
CMPX WILL FLY TOMORROW!
▲ 1
💬 1
⚡ 0.1
CMPX WILL FLY TOMORROW
▲ 1
💬 1
⚡ 0.2
CMPX TOMORROW
▲ 1
💬 1
⚡ 0.5
CMPX IS A STOCK TO WATCH!
▲ 1
💬 0
⚡ 0.5
CMPX is A stock to watch!
▲ 1
💬 1
⚡ 0.5
CMPX is a stock to watch!
▲ 1
💬 1
⚡ 0.5
CMPX!!!!!!!!!!
▲ 1
💬 0
⚡ 0.5
CMPX!!!!!!!
▲ 1
💬 0
⚡ 0.5
$CMPX: Upcoming catalyst Pre-BLA Meeting, $195M War Chest, and the Crossover Nobody's Talking About;
▲ 1
💬 1
⚡ 0.5
Thoughts on CMPX 65% drop
▲ 1
💬 0
⚡ 0.5
Thoughts on CMPX 65% drop
▲ 1
💬 1
⚡ 0.5
May 28, 2026
other
Compass Therapeutics to Participate in Upcoming June Investor Events
<p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceut
May 21, 2026
fda
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
<p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company
May 17, 2026
Clinical Trial
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
Phase Phase 2 — COMPLETED
May 13, 2026
earnings_calendar
CMPX Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
other
Compass Therapeutics to Participate in Upcoming May Investor Events
<p>BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company
May 8, 2026
short_interest
FTD: CMPX — 1,450,764 shares ($2.6M) failed to deliver
Settlement: 20260508, Price: $1.81, FTD Value: $2,625,882.84, COMPASS THERAPEUTICS INC COM
May 6, 2026
earnings_calendar
CMPX Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
earnings
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
<p>BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company
Apr 30, 2026
Clinical Trial
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Phase Phase 3 — COMPLETED
Apr 27, 2026
fda
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig Demonstrates Significant Benefit in Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Apr 24, 2026
fda
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
<p>BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical compan
Apr 24, 2026
short_volume
Short Volume: CMPX — 73.2% short (1.1M / 1.5M)
Short: 1,109,621 | Exempt: 8,914 | TRF Vol: 1,515,014 | Short Ratio: 73.2% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: CMPX — 74.5% short (0.5M / 0.6M)
Short: 482,068 | Exempt: 0 | TRF Vol: 647,359 | Short Ratio: 74.5% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: CMPX — 61.7% short (0.7M / 1.1M)
Short: 699,402 | Exempt: 5,680 | TRF Vol: 1,132,882 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: CMPX — 62.0% short (0.8M / 1.4M)
Short: 840,535 | Exempt: 59,522 | TRF Vol: 1,354,910 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_interest
FTD: CMPX — 99,932 shares ($0.6M) failed to deliver
Settlement: 20260420, Price: $6.00, FTD Value: $599,592, COMPASS THERAPEUTICS INC COM
Apr 17, 2026
short_interest
FTD: CMPX — 93,631 shares ($0.6M) failed to deliver
Settlement: 20260417, Price: $6.53, FTD Value: $611,410.43, COMPASS THERAPEUTICS INC COM